Quantification of carbonic anhydrase gene expression in ventricle of hypertrophic and failing human heart

BMC Cardiovascular Disorders

Joseph R Casey¹  John Mullen²  Anita L Quon¹  Bernardo V Alvarez³ 

[1] Department of Biochemistry, and Membrane Protein Disease Research Group, University of Alberta, Edmonton, AB, T6G 2H7, Canada;Department of Surgery, University of Alberta, Edmonton, AB, T6G 2H7, Canada;Universidad Nacional de La Plata, La Plata, Argentina

关键词: Cardiac hypertrophy;    Heart transplant;    Gene expression;    pH regulation;    Carbonic anhydrase;    Heart failure;   

Others  :  857907
DOI  :  10.1186/1471-2261-13-2

 received in 2012-09-11, accepted in 2012-12-17,  发布年份 2013

【 摘 要 】

Background

Carbonic anhydrase enzymes (CA) catalyze the reversible hydration of carbon dioxide to bicarbonate in mammalian cells. Trans-membrane transport of CA-produced bicarbonate contributes significantly to cellular pH regulation. A body of evidence implicates pH-regulatory processes in the hypertrophic growth pathway characteristic of hearts as they fail. In particular, Na⁺/H⁺ exchange (NHE) activation is pro-hypertrophic and CA activity activates NHE. Recently Cardrase (6-ethoxyzolamide), a CA inhibitor, was found to prevent and revert agonist-stimulated cardiac hypertrophy (CH) in cultured cardiomyocytes. Our goal thus was to determine whether hypertrophied human hearts have altered expression of CA isoforms.

Methods

We measured CA expression in hypertrophied human hearts to begin to examine the role of carbonic anhydrase in progression of human heart failure. Ventricular biopsies were obtained from patients undergoing cardiac surgery (CS, n = 14), or heart transplantation (HT, n = 13). CS patients presented mild/moderate concentric left ventricular hypertrophy and normal right ventricles, with preserved ventricular function; ejection fractions were ~60%. Conversely, HT patients with failing hearts presented CH or ventricular dilation accompanied by ventricular dysfunction and EF values of 20%. Non-hypertrophic, non-dilated ventricular samples served as controls.

Results

Expression of atrial and brain natriuretic peptide (ANP and BNP) were markers of CH. Hypertrophic ventricles presented increased expression of CAII, CAIV, ANP, and BNP, mRNA levels, which increased in failing hearts, measured by quantitative real-time PCR. CAII, CAIV, and ANP protein expression also increased approximately two-fold in hypertrophic/dilated ventricles.

Conclusions

These results, combined with in vitro data that CA inhibition prevents and reverts CH, suggest that increased carbonic anhydrase expression is a prognostic molecular marker of cardiac hypertrophy.

【 授权许可】

   
2013 Alvarez et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]McMurray JJ, Pfeffer MA: Heart failure. Lancet 2005, 365(9474):1877-1889.
• [2]Kusumoto K, Haist JV, Karmazyn M: Na+/H+ exchange inhibition reduces hypertrophy and heart failure after myocardial infarction in rats. Am J Physiol Heart Circ Physiol 2001, 280(2):H738-H745.
• [3]Karmazyn M, Sostaric JV, Gan XT: The myocardial Na+/H+ exchanger: a potential therapeutic target for the prevention of myocardial ischaemic and reperfusion injury and attenuation of postinfarction heart failure. Drugs 2001, 61(3):375-389.
• [4]Cingolani HE, Ennis IL: Sodium-hydrogen exchanger, cardiac overload, and myocardial hypertrophy. Circulation 2007, 115(9):1090-1100.
• [5]Engelhardt S, Hein L, Keller U, Klambt K, Lohse MJ: Inhibition of Na+-H+ exchange prevents hypertrophy, fibrosis, and heart failure in beta(1)-adrenergic receptor transgenic mice. Circ Res 2002, 90(7):814-819.
• [6]Yokoyama H, Gunasegaram S, Harding SE, Avkiran M: Sarcolemmal Na+/H+ exchanger activity and expression in human ventricular myocardium. J Am Coll Cardiol 2000, 36(2):534-540.
• [7]Ikeda T, Schmitt B, Pouyssegur J, Wakabayashi S, Shigekawa M: Identification of cytoplasmic subdomains that control pH-sensing of the Na+/H + exchanger (NHE1): pH-maintenance, ATP-sensitive, and flexible loop domains. J Biochem 1997, 121(2):295-303.
• [8]Wakabayashi S, Bertrand B, Shigekawa M, Fafournoux P, Pouyssegur J: Growth factor activation and “H+-sensing” of the Na+/H+ exchanger isoform 1 (NHE1). Evidence for an additional mechanism not requiring direct phosphorylation. J Biol Chem 1994, 269(8):5583-5588.
• [9]Perez NG, Alvarez BV, de Hurtado MC C, Cingolani HE: pHi regulation in myocardium of the spontaneously hypertensive rat. Compensated enhanced activity of the Na+-H+ exchanger. Circ Res 1995, 77(6):1192-1200.
• [10]Sterling D, Reithmeier RA, Casey JR: A transport metabolon. Functional interaction of carbonic anhydrase II and chloride/bicarbonate exchangers. J Biol Chem 2001, 276(51):47886-47894.
• [11]Li X, Alvarez B, Casey JR, Reithmeier RAF, Fliegel L: Carbonic anhydrase II binds to and enhances activity of the Na+/H+ exchanger. J Biol Chem 2002, 277:36085-36091.
• [12]Cordat E, Casey JR: Bicarbonate transport in cell physiology and disease. Biochem J 2009, 417:423-439.
• [13]Alvarez BV, Johnson DE, Sowah D, Soliman D, Light P, Xia Y, Karmazyn M, Casey JR: Carbonic anhydrase inhibition prevents and reverts cardiomyocyte hypertrophy. J Physiol 2007, 579:127-145.
• [14]Moyer JH, Ford RV: Laboratory and clinical observations on ethoxzolamide (cardrase) as a diuretic agent. Am J Cardiol 1958, 1(4):497-504.
• [15]Nakamura TY, Iwata Y, Arai Y, Komamura K, Wakabayashi S: Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure. Circ Res 2008, 103(8):891-899.
• [16]Sterling D, Casey JR: Transport activity of AE3 chloride/bicarbonate anion-exchange proteins and their regulation by intracellular pH. Biochem J 1999, 344(Pt 1):221-229.
• [17]Alvarez B, Loiselle FB, Supuran CT, Schwartz GJ, Casey JR: Direct extracellular interaction between carbonic anhydrase IV and the NBC1 Na+/HCO3- co-transporter. Biochemistry 2003, 42:2321-2329.
• [18]Casey JR, Sly WS, Shah GN, Alvarez BV: Bicarbonate homeostasis in excitable tissues: role of AE3 Cl-/HCO3- exchanger and carbonic anhydrase XIV interaction. Am J Physiol 2009, 297:C526-C536.
• [19]Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, et al.: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112(12):e154-e235.
• [20]Saito Y, Nakao K, Arai H, Sugawara A, Morii N, Yamada T, Itoh H, Shiono S, Mukoyama M, Obata K, et al.: Atrial natriuretic polypeptide (ANP) in human ventricle. Increased gene expression of ANP in dilated cardiomyopathy. Biochem Biophys Res Commun 1987, 148(1):211-217.
• [21]Saito Y, Nakao K, Arai H, Nishimura K, Okumura K, Obata K, Takemura G, Fujiwara H, Sugawara A, Yamada T, et al.: Augmented expression of atrial natriuretic polypeptide gene in ventricle of human failing heart. J Clin Invest 1989, 83(1):298-305.
• [22]Vuillemin M, Pexieder T: Carbonic anhydrase II expression pattern in mouse embryonic and fetal heart. Anat Embryol (Berl) 1997, 195(3):267-277.
• [23]Sterling D, Alvarez BV, Casey JR: The extracellular component of a transport metabolon: Extracellular loop 4 of the human AE1 Cl-/HCO3- exchanger binds carbonic anhydrase IV. J Biol Chem 2002, 277:25239-25246.
• [24]Frey N, Olson EN: Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003, 65:45-79.
• [25]Sharkey LC, McCune SA, Yuan O, Lange C, Fray J: Spontaneous pregnancy-induced hypertension and intrauterine growth restriction in rats. Am J Hypertens 2001, 14(10):1058-1066.
• [26]Domenighetti AA, Wang Q, Egger M, Richards SM, Pedrazzini T, Delbridge LM: Angiotensin II-mediated phenotypic cardiomyocyte remodeling leads to age-dependent cardiac dysfunction and failure. Hypertension 2005, 46(2):426-432.
• [27]Domenighetti AA, Ritchie M, Smyth G, Pedrazzini T, Proietto J, Delbridge LMD: Gene expression profiling reveals distinct sets of genes altered during hormonally and metabolically induced cardiac hypertrophies. J Mol Cell Cardiol 2004, 37:303.
• [28]Lee RT, Bloch KD, Pfeffer JM, Pfeffer MA, Neer EJ, Seidman CE: Atrial natriuretic factor gene expression in ventricles of rats with spontaneous biventricular hypertrophy. J Clin Invest 1988, 81(2):431-434.
• [29]Li X, Liu Y, Alvarez BV, Casey JR, Fliegel L: A novel carbonic anhydrase II binding site regulates NHE1 activity. Biochemistry 2006, 45(7):2414-2424.
• [30]de Hurtado MC C, Alvarez BV, Perez NG, Ennis IL, Cingolani HE: Angiotensin II activates Na+-independent Cl--HCO3- exchange in ventricular myocardium. Circ Res 1998, 82(4):473-481.
• [31]de Hurtado MC C, Alvarez BV, Ennis IL, Cingolani HE: Stimulation of myocardial Na+-independent Cl--HCO3- exchanger by angiotensin II is mediated by endogenous endothelin. Circ Res 2000, 86(6):622-627.
• [32]Perez NG, de Hurtado MC, Cingolani HE: Reverse mode of the Na+-Ca2+ exchange after myocardial stretch: underlying mechanism of the slow force response. Circ Res 2001, 88(4):376-382.
• [33]Cingolani HE, Camilion De Hurtado MC: Na+-H+ exchanger inhibition: a new antihypertrophic tool. Circ Res 2002, 90(7):751-753.
• [34]Brown B, Quon A, Casey JR: Carbonic Anhydrase II Promotes Cardiomyocyte Hypertrophy. Can J Physiol Pharmacol 2012. In Press
• [35]Lewis SE, Erickson RP, Barnett LB, Venta PJ, Tashian RE: N-ethyl-N-nitrosourea-induced null mutation at the mouse Car-2 locus: an animal model for human carbonic anhydrase II deficiency syndrome. Proc Natl Acad Sci U S A 1988, 85(6):1962-1966.
• [36]Ch’en FF, Villafuerte FC, Swietach P, Cobden PM, Vaughan-Jones RD: S0859, an N-cyanosulphonamide inhibitor of sodium-bicarbonate cotransport in the heart. Br J Pharmacol 2008, 153(5):972-982.
• [37]Vaughan-Jones RD, Spitzer KW, Swietach P: Intracellular pH regulation in heart. J Mol Cell Cardiol 2009, 46(3):318-331.
• [38]Saegusa N, Moorhouse E, Vaughan-Jones RD, Spitzer KW: Influence of pH on Ca2+ current and its control of electrical and Ca2+ signaling in ventricular myocytes. J Gen Physiol 2011, 138(5):537-559.
• [39]Johnson DE, Casey JR: Cytosolic H+ Microdomain Developed Around AE1 During AE1-Mediated Cl-/HCO3- Exchange. J Physiol 2011, 589:1551-1569.
• [40]Leaf A, Schwartz WB, Relman AS: Oral administration of a potent carbonic anhydrase inhibitor (diamox). I. Changes in electrolyte and acid–base balance. N Engl J Med 1954, 250(18):759-764.
• [41]Relman AS, Leaf A, Schwartz WB: Oral administration of a potent carbonic anhydrase inhibitor (Diamox). II. Its use as a diuretic in patients with severe congestive heart failure. N Engl J Med 1954, 250(19):800-804.
• [42]Moyer JH, Hughes WM: A comparative study of neohydrin and diamox when used alone and in combination for the treatment of severe congestive heart failure. J Chronic Dis 1955, 2(6):678-686.
• [43]Moffett BS, Moffett TI, Dickerson HA: Acetazolamide therapy for hypochloremic metabolic alkalosis in pediatric patients with heart disease. Am J Ther 2007, 14(4):331-335.
• [44]Kittleson MM, Ye SQ, Irizarry RA, Minhas KM, Edness G, Conte JV, Parmigiani G, Miller LW, Chen Y, Hall JL, et al.: Identification of a gene expression profile that differentiates between ischemic and nonischemic cardiomyopathy. Circulation 2004, 110(22):3444-3451.
• [45]Maisel A: B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what’s next? Circulation 2002, 105(20):2328-2331.
• [46]Wieczorek SJ, Wu AH, Christenson R, Krishnaswamy P, Gottlieb S, Rosano T, Hager D, Gardetto N, Chiu A, Bailly KR, et al.: A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J 2002, 144(5):834-839.
• [47]Braunwald E: Biomarkers in heart failure. N Engl J Med 2008, 358(20):2148-2159.